Janus kinase inhibitors for the treatment of atopic dermatitis: Real-life data on efficacy and safety in light of the Pharmacovigilance Risk Assessment Committee recommended measures

被引：3

作者：

Reguiai, Z. ^{[1
,20
]}

Becherel, P. A. ^{[2
]}

Fougerousse, A. C. ^{[3
]}

Chaby, G. ^{[4
]}

Perrot, J. L. ^{[5
]}

Begon, E. ^{[6
]}

Jacobzone-Leveque, C. ^{[7
]}

Boulard, C. ^{[8
]}

Badaoui, A. ^{[9
]}

Poreaux, C. ^{[10
]}

David, L. ^{[11
]}

Quiles-Tsimaratos, N. ^{[11
]}

Lons-Danic, D. ^{[12
]}

Fite, C. ^{[12
]}

Liegeon, A. -l. ^{[13
]}

Patchinsky, A. ^{[13
]}

Parier, J. ^{[14
,15
]}

Garcia, C. ^{[16
]}

Esteve, E. ^{[17
]}

Mohty, R. ^{[18
]}

Mery-Bossard, L. ^{[19
]}

Maccari, F. ^{[3
,15
]}

机构：

[1] Polyclin Courlancy, Dept Dermatol, Reims, France

[2] Antony Hosp, Dermatol & Clin Immunol Unit, Antony, France

[3] Hop Instruct Armees Begin, Dept Dermatol, St Mande, France

[4] CHU Amiens Picardie, Dept Dermatol, Amiens, France

[5] CHU St Etienne, Dept Dermatol, St Etienne, France

[6] Ctr Hosp Rene Dubos, Dept Dermatol, Pontoise, France

[7] Ctr Hosp Bretagne Sud, Dept Dermatol, Lorient, France

[8] Ctr Hosp Le Havre, Dept Dermatol, Le Havre, France

[9] Cabinet Med, Paris, France

[10] Clin Pasteur, Ctr Dermatol Stanislas, Nancy, France

[11] Hop St Joseph, Dept Dermatol, Marseille, France

[12] Hop Paris St Joseph, Dept Dermatol, Paris, France

[13] Ctr Hosp Reg Metz Thionville, Dept Dermatol, Thionville, France

[14] Hop St Louis, Ctr Sante Sabouraud, Paris, France

[15] Cabinet Med, St Maur Des Fosses, France

[16] Ctr Hosp Emile Roux, Dept Dermatol, Le Puy En Velay, France

[17] Ctr Hosp Orleans, Dept Dermatol, Orleans, France

[18] Cabinet Med, Beauvais, France

[19] CHI Poissy St Germain, Dept Dermatol, St Germain En Laye, France

[20] Polyclin Courlancy Bezannes, Dept Dermatol, 89 Rue Louis Victor Broglie, F-51430 Bezannes, France

来源：

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY | 2023年 / 37卷 / 11期

关键词：

D O I：

10.1111/jdv.19302

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

引用

页码：E1307 / E1309

页数：3

共 10 条

[1] Safety of baricitinib for the treatment of atopic dermatitis over a median of 1.6 years and up to 3.9 years of treatment: an updated integrated analysis of eight clinical trials [J].

Bieber, Thomas ;

Katoh, Norito ;

Simpson, Eric L. ;

de Bruin-Weller, Marjolein ;

Thaci, Diamant ;

Torrelo, Antonio ;

Sontag, Angelina ;

Grond, Susanne ;

Issa, Maher ;

Lu, Xiaoyu ;

Cardillo, Tracy ;

Holzwarth, Katrin ;

Thyssen, Jacob P. .

JOURNAL OF DERMATOLOGICAL TREATMENT, 2023, 34 (01)

[2]

Boesjes Celeste M, 2022, Acta Derm Venereol, V102, padv00820, DOI [10.2340/actadv.v102.3978, 10.2340/actadv.v102.3978]

[3] Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis [J].

Burmester, Gerd R. ;

Cohen, Stanley B. ;

Winthrop, Kevin L. ;

Nash, Peter ;

Irvine, Alan D. ;

Deodhar, Atul ;

Mysler, Eduardo ;

Tanaka, Yoshiya ;

Liu, John ;

Lacerda, Ana P. ;

Palac, Hannah ;

Shaw, Tim ;

Mease, Philip J. ;

Guttman-Yassky, Emma .

RMD OPEN, 2023, 9 (01)

[4] Real-Life Effectiveness and Safety of Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: A Single-Center 16-Week Study [J].

Gargiulo, Luigi ;

Ibba, Luciano ;

Cortese, Andrea ;

Avagliano, Jessica ;

Valenti, Mario ;

Costanzo, Antonio ;

Narcisi, Alessandra .

DERMATOLOGY AND THERAPY, 2023, 13 (02) :651-660

[5] Evaluation of VTE, MACE, and Serious Infections Among Patients with RA Treated with Baricitinib Compared to TNFi: A Multi-Database Study of Patients in Routine Care Using Disease Registries and Claims Databases [J].

Salinas, Claudia A. ;

Louder, Anthony ;

Polinski, Jennifer ;

Zhang, Tancy C. ;

Bower, Hannah ;

Phillips, Syd ;

Song, Yufei ;

Rashidi, Emaan ;

Bosan, Rafia ;

Chang, Hsiu-Ching ;

Foster, Nicole ;

Gershenson, Bernice ;

Yamanaka, Hisashi ;

Kishimoto, Mitsumasa ;

Tanaka, Yoshiya ;

Fischer, Peter ;

Zhu, Baojin ;

Faries, Douglas ;

Mai, Xiaodan ;

Doherty, Brett T. ;

Grelaud, Angela ;

Thurin, Nicolas H. ;

Askling, Johan ;

Deberdt, Walter .

RHEUMATOLOGY AND THERAPY, 2023, 10 (01) :201-223

[6] Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis Analysis of Follow-up Data From the Measure Up 1 and Measure Up 2 Randomized Clinical Trials [J].

Simpson, Eric L. ;

Papp, Kim A. ;

Blauvelt, Andrew ;

Chu, Chia-Yu ;

Hong, H. Chih-Ho ;

Katoh, Norito ;

Calimlim, Brian M. ;

Thyssen, Jacob P. ;

Chiou, Albert S. ;

Bissonnette, Robert ;

Gold, Linda F. Stein ;

Wegzyn, Colleen ;

Hu, Xiaofei ;

Liu, Meng ;

Liu, John ;

Tenorio, Allan R. ;

Chu, Alvina D. ;

Guttman-Yassky, Emma .

JAMA DERMATOLOGY, 2022, 158 (04) :404-413

[7] The underrepresentation of older adults in clinical trials of Janus kinase inhibitors in the treatment of atopic dermatitis [J].

Sreekantaswamy, Shreya A. ;

Tully, Janell ;

Edelman, Linda S. ;

Supiano, Mark A. ;

Butler, Daniel .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (05) :1174-1176

[8] Effectiveness and tolerance of Janus kinase inhibitors for the treatment of recalcitrant atopic dermatitis in a real-life French multicenter adult cohort [J].

Vanlerberghe, Julia ;

Dezoteux, Frederic ;

Martin, Claire ;

Jachiet, Marie ;

Soria, Angele ;

Tetart, Florence ;

Modeste-Duval, Anne-Benedicte ;

Bursztejn, Anne-Claire ;

Misery, Laurent ;

Aubin, Francois ;

Lasek, Audrey ;

Leleu, Camille ;

Du-Thanh, Aurelie ;

Pasteur, Justine ;

Pralong, Pauline ;

Nosbaum, Audrey ;

Droitcourt, Catherine ;

Viguier, Manuelle ;

Tauber, Marie ;

Seneschal, Julien ;

Barbarot, Sebastien ;

Staumont-Salle, Delphine .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 88 (04) :900-904

[9] Comparative efficacy and safety of abrocitinib, baricitinib, and upadacitinib for moderate-to-severe atopic dermatitis: A network meta-analysis [J].

Wan, Huiying ;

Jia, Haiping ;

Xia, Tian ;

Zhang, Dingding .

DERMATOLOGIC THERAPY, 2022, 35 (09)

[10]

Ytterberg SR, 2022, NEW ENGL J MED, V386, P316, DOI [10.1056/NEJMoa2109927, 10.1056/NEJMc2202778]

← 1 →